HIF-1α inhibition could be relevant to the resolution of all NAFLD-related clinical parameters (including steatosis, chronic hepatitis, and fibrosis) and HCC, whereas its activation is relevant to the protection against ischemia/reperfusion- (I/R-) related injury and acute hepatitis [59]. The gene discussed is HIF1A; the disease is steatosis.